Literature DB >> 20159362

Development of hypoxia in a preclinical model of tumor micrometastases.

Trude G Simonsen1, Jon-Vidar Gaustad, Einar K Rofstad.   

Abstract

PURPOSE: Hypoxic regions have been shown to be a characteristic feature of a wide variety of human primary tumors, whereas the oxygenation status of subclinical micrometastases is in general unknown. The development of hypoxia in a xenograft model of microscopic metastases was investigated in this study. METHODS AND MATERIALS: U-25-GFP human melanomas growing in dorsal window chamber preparations in BALB/c nu/nu mice were used as a preclinical model of micrometastases. Tumor blood supply time and morphologic parameters of the vascular network were determined from first-pass imaging movies and vascular maps recorded by use of 155-kDa tetramethylrhodamine isothiocyanate-labeled dextran as a vascular tracer. Tumor hypoxia was assessed from immunohistochemical preparations of the imaged tissue by use of pimonidazole as a hypoxia marker.
RESULTS: Nearly half of the tumors had developed hypoxic regions when they reached a diameter of 2 to 3 mm. Tumors with multiple hypoxic foci showed a low growth rate, low blood flow velocity, high vessel tortuosity, high vessel segment length, and high vascular density, whereas tumors with a single hypoxic region showed a high growth rate, high blood flow velocity, low vessel tortuosity, low vessel segment length, and low vascular density. The tumors with hypoxic regions did not differ from those without hypoxia in any single parameter.
CONCLUSIONS: U-25-GFP xenograft models of vascularized human tumor micrometastases may develop hypoxic regions as a consequence of two distinctly different morphologic abnormalities in the vascular network: high resistance against blood flow (i.e., high vessel tortuosity and high vessel segment length) or low vascular density. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159362     DOI: 10.1016/j.ijrobp.2009.09.045

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

2.  Quorum-sensing Salmonella selectively trigger protein expression within tumors.

Authors:  Charles A Swofford; Nele Van Dessel; Neil S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

Review 3.  Targeting hypoxic tumour cells to overcome metastasis.

Authors:  Kevin L Bennewith; Shoukat Dedhar
Journal:  BMC Cancer       Date:  2011-11-30       Impact factor: 4.430

4.  Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure.

Authors:  Tord Hompland; Christine Ellingsen; Einar K Rofstad
Journal:  BMC Cancer       Date:  2012-11-22       Impact factor: 4.430

5.  Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.

Authors:  Yudong Wang; Filip Janku; Sarina Piha-Paul; Kenneth Hess; Russell Broaddus; Lidong Liu; Naiyi Shi; Michael Overman; Scott Kopetz; Vivek Subbiah; Aung Naing; David Hong; Apostolia M Tsimberidou; Daniel Karp; James Yao; Siqing Fu
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.